Almac’s Diagnostics will be the central service lab to perform the analytic phase and deliver to the clinicians the result of Exonhit AclarusDx diagnostic test.

Exonhit AclarusDx is a micro-array-based test intended to aid in the diagnosis of Alzheimer’s disease (AD) by detecting biomarkers specific for AD in peripheral blood. The test was CE marked in March 2011 and has been introduced for clinical diagnostic use in France. The test will be performed by Almac from its ISO17025-accredited laboratory. Almac will deliver AclarusDx result to the clinicians.

AclarusDx is the second commercial clinical test to be managed by Almac. Almac will deliver a range of novel, validated biomarker assays from its Clinical Testing Laboratory to facilitate the stratification and enrichment of prospective clinical trials.

Loïc Maurel, M.D., of Exonhit said, “We chose Almac Diagnostics as our reference lab to perform the analytic phase of AclarusDx due to its strong expertise in molecular biology and its practice of the Affymetrix platform. We also view the location of Almac Diagnostics in Northern Ireland as an asset for the upcoming roll-out of AclarusDx in Europe.”